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ABSTRACT  
As the population ages, heart failure will continue to be a growing public health 30 
problem. Metabolic homeostasis in the heart requires a fine-tuning of metabolism of 
different substrates. Notwithstanding a retro control of fatty acid and glucose 
utilization, the heart functions best when it oxidizes both substrates simultaneously. 
Mismatch between the uptake and oxidation of long-chain fatty acids in the 
myocardium induces lipotoxicity characterized by the accumulation of triglycerides, 35 
diacylglycerols, ceramides, and other lipids. Lipotoxicity may result in cardiomyocyte 
apoptosis, interstitial fibrosis, and cardiac dysfunction, and may promote insulin 
resistance. In this review, we will highlight the impact of lipids and lipoproteins on 
myocardial biology and on the development of heart failure independent of their 
effects on coronary heart disease. 40 
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1. Introduction: epidemiological perspective of heart failure 
Cardiovascular diseases remain the leading cause of mortality in Europe, causing 46% 55 
of all deaths[1]. These disorders cause a greater proportion of deaths among women 
(51%) than among men (42%)[1]. However, these deaths are more likely to occur in 
old age in women. The dramatic decline of the age-adjusted death rate for coronary 
heart disease and for stroke in the United States and in Europe[2] in the past 4 decades 
has led to a clear underestimation of the real impact of these diseases as reflected by 60 
crude mortality data.  
The incidence and prevalence of heart failure are increasing[3]. The 5-year age-
adjusted mortality rates after onset of heart failure are 50% in men and 46% in 
women[4]. Heart failure is the cardiovascular disease of this century in Europe and in 
the United States. As the population ages, heart failure will continue to be a growing 65 
public health problem. In this review, we will highlight the impact of lipids and 
lipoproteins on myocardial biology and on the development of heart failure 
independent of their effects on coronary heart disease. Since coronary heart disease 
indirectly influences the incidence of heart failure, we will briefly discuss prevention 
of coronary heart disease by dietary interventions in the next section with an emphasis 70 
on the controversial nature of dietary guidelines and on recent progress in this field. 
 
2. Diet and prevention of coronary heart disease 
The low-fat ‘diet-heart hypothesis’ has been the cornerstone of recommendations 
promulgated vigorously by the National Cholesterol Education Program, the National 75 
Institutes of Health, and the American Heart Association. This low-fat ‘diet-heart 
hypothesis’ dominated nutritional thought for several decades. However, these dietary 
recommendations have always been controversial given the lack of scientific evidence 
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and have come under intense attack for more than 10 years[5, 6].  The promotion of 
the low-fat diet was inspired by the classic Seven Countries Study that showed a 80 
direct correlation between dietary fat and total cholesterol levels and between total 
cholesterol levels and coronary-related mortality[5]. Surprisingly, the promotion of 
the low-fat diet began in earnest with the National Institutes of Health (NIH)-
sponsored Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), 
which demonstrated that cholestyramine resulted in a 19% reduction in risk (p <0.05) 85 
of the primary end-point composed of coronary mortality and nonfatal myocardial 
infarction[7]. A leap of faith was made: if lowering serum cholesterol by medication 
was effective against coronary artery disease, reducing serum cholesterol by 
decreasing  (saturated) fat intake would produce a similar result[6]. 
It should be stressed that the investigators of the Seven Countries Study did not claim 90 
causal relationships[8]. The relationship between diet and coronary heart disease is 
more complex. Serum cholesterol is not an intermediate variable that captures the 
complete effect of the diet. As a matter of fact, Ancel Keys, the lead investigator of 
the Seven Countries Study, observed in the early 1950s very low incidences 
of coronary heart disease in Naples and became a strong proponent of the ‘good 95 
Mediterranean diet’[9]. The traditional Mediterranean diet was the diet found in olive 
growing areas of Crete, Greece, and Southern Italy in the late 1950s. Although there 
is heterogeneity in this diet in different geographic areas around the Mediterranean 
sea, the general characteristics can be summarized as follows: 1) a high consumption 
of cereals, legumes, nuts, vegetables, and fruits; 2) a relatively high-fat consumption, 100 
mostly provided by olive oil; 3) moderate to high fish consumption; 4) poultry and 
dairy products consumed in moderate to small amounts; 5) low consumption of red 
meats, and meat products; and 6) moderate alcohol intake, usually in the form of red 
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wine. In 1996, a protective effect of the Mediterranean diet was demonstrated in the 
Lyon Diet Heart Study[10]. The Lyon Diet Heart Study was a secondary prevention 105 
trial testing the protective effects of a Mediterranean type of diet supplemented with 
rapeseed oil and margarine (a source of α-linolenic acid (C18:3, n−3)) to replace 
butter and cream in the experimental group.  
In 2013, the results of the landmark primary prevention PREDIMED trial were 
published[11]. A total of 7447 participants with no cardiovascular disease at 110 
enrollment were randomized to one of three diets: a Mediterranean diet supplemented 
with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a 
control diet (advice to reduce dietary fat). The primary endpoint was the rate of major 
cardiovascular events (myocardial infarction, stroke, or death from cardiovascular 
causes). On the basis of the results of an interim analysis, the trial was stopped after a 115 
median follow-up of 4.8 years. The multivariable-adjusted hazard ratios were 0.70 
(95% confidence interval [CI], 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the 
group assigned to the Mediterranean diet with extra-virgin olive oil and for the group 
assigned to the Mediterranean diet with nuts, respectively, versus the control group. 
The Lyon Diet Heart Study in a secondary prevention setting and the PREDIMED 120 
study in a primary prevention setting provide strong evidence that the Mediterranean 
diet has become the standard for prevention of coronary events and for healthy eating. 
These studies, together with the important epidemiological data of Trichopoulou et 
al.[12], confirm the importance of the whole dietary pattern approach to preventive 
nutrition. A healthy diet should be thought of as a whole rather than as a recitation of 125 
good and bad components. In other words, the interactions between various nutrients 
is the real biological source of protection rather than any small change in specific 
nutrients[13]. This principle should also be kept in mind when studying the relation 
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between lipids and heart failure: a reductionist approach is hypothesis generating but 
does not provide any final answer. 130 
 
3. Lipids as fuel for the heart 
The stroke work is the work done by the ventricle to eject the stroke volume and 
corresponds to the area within the pressure-volume loop. Since the heart is 
continuously producing external work by ejecting blood into the aorta,	  the energetic 135 
requirements of this organ are well beyond the normal maintenance of cellular 
integrity[14]. Cardiac energy conversion is highly specialized to maintain 
physiological concentrations of energy-rich phosphate bonds under conditions of 
large variations of external work. The maintenance of cellular metabolites during 
alterations in workload has been termed metabolic homeostasis[14]. The heart has a 140 
relatively low ATP content (5 µmol per g wet weight) and a high rate of ATP 
hydrolysis (approximately	   30 µmol per g wet weight per minute at rest)[15-17]. 
Hence, there is complete turnover of the myocardial ATP pool approximately every 
10 seconds under normal conditions. The daily turnover of ATP in the human heart 
(13 mol or more than 6 kg) is many times higher than the weight of the heart[18]. 145 
Metabolic homeostasis requires a fine-tuning of cardiac metabolism of different 
substrates. Except in the postprandial period, the heart predominantly metabolizes free 
fatty acids (up to 70%). Notwithstanding a retro control of fatty acid and glucose 
utilization, the heart functions best when it oxidizes both substrates 
simultaneously[19]. Other competing energy substrates are lactate, ketones, and 150 
amino acids. A schematic overview of fatty acid ß-oxidation in cardiomyocytes and 
its reciprocal relationship with glucose metabolism is shown in Figure 1. 
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Fatty acids are supplied to the heart as either free fatty acids bound to albumin or as 
fatty acids released from triglycerides contained in chylomicrons or very-low-density 
lipoproteins (VLDL)[15]. The majority of lipids entering cardiac cells are diverted 155 
toward fatty acid utilization[20] with some being stored or used for structural 
requirements. The intramyocardial content of triglycerides in healthy subjects 
(approximately 3 mg per g tissue) is very low compared to the rate of free fatty acid 
uptake (approximately 3 mg per g tissue per hour)[15]. If 20% of the cardiac free fatty 
acid uptake enters the intramyocardial triglyceride pool[21], the mean turnover time 160 
for intramyocardial triglycerides is only 5 hours.  
Normal circulating free fatty acid concentrations range between 0.2 mM and 0.6 
mM[22]. Activation of the sympathetic nervous system, e.g. during effort or during 
fasting, results in increased circulating free fatty acid concentrations primarily 
resulting from β-adrenoreceptor-mediated stimulation of hormone-sensitive lipase 165 
activity in the adipose tissue[23]. Chronically elevated circulating free fatty acid 
concentrations occur in obese, insulin resistant subjects with dysregulated lipolysis 
and in patients with overt diabetes. The arterial fatty acid concentration is the primary 
determinant of the rate of myocardial fatty acid uptake and oxidation[20].  The 
majority of fatty acids used by the heart that originate from exogenous triglycerides 170 
are derived from chylomicrons and only a minor portion originates from VLDL[24]. 
Triglycerides within chylomicrons and VLDL require hydrolysis by lipoprotein lipase 
on the luminal surface of endothelial cells[25]. Lipoprotein lipase is associated with 
proteoglycans and glycosylphosphatidylinositol anchored high-density lipoprotein 
binding protein 1 (GPIHBP1). Free fatty acids originating from either albumin or 175 
generated by the action of lipoprotein lipase in the capillary endothelium enter the 
cardiomyocyte either by passive diffusion or via protein carrier-mediated 
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pathways[25]. Uptake of whole triglyceride-rich lipoproteins in the heart may occur 
via the VLDL receptor[26]. Myocardial fatty acids can also be derived from de novo 
lipogenesis[25]. Deletion of fatty acid synthetase in heart of mice results in cardiac 180 
decompensation in the setting of aortic constriction or aging[27]. 
The Randle cycle, also known as the glucose fatty-acid cycle, describes the reciprocal 
relationship between fatty acid and glucose metabolism[28]. Pyruvate 
decarboxylation is the key irreversible step in carbohydrate oxidation and is catalyzed 
by pyruvate dehydrogenase, which is located in the mitochondrial matrix. Increased 185 
generation of acetyl coenzyme A (acetyl CoA) derived from fatty acid β-oxidation 
decreases pyruvate dehydrogenase activity via the activation of pyruvate 
dehydrogenase kinase and the subsequent phosphorylation and inhibition of pyruvate 
dehydrogenase. Both an increased acetyl CoA/CoA ratio and an increased 
NADH/NAD+ ratio result in activation of pyruvate dehydrogenase kinase. Increased 190 
fatty acid β-oxidation also decreases glycolysis via inhibition of phosphofructokinase 
isoforms 1 and 2 mediated via increased cytosolic citrate concentrations. On the other 
hand, increased glucose oxidation will result in inhibition of fatty acid oxidation. 
Acetyl CoA transferred from the mitochondria to the cytosol is a substrate for acetyl 
CoA carboxylase, which generates malonyl CoA. Malonyl CoA inhibits carnitine 195 
palmitoyltransferase I, which is the rate-limiting enzyme in the carnitine 
palmitoyltransferase system. This system allows transfer of fatty acids to the 
mitochondria for ß-oxidation. 
As in any mechanical pump, only part of the energy invested by the heart is converted 
to external power[29]. The mechanical efficiency is defined as the ratio of useful 200 
energy produced (stroke work) to oxygen consumed[30]. Invasive studies in healthy 
control subjects have demonstrated that approximately 25% of consumed oxygen is 
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finally converted to external work[30]. The residual energy is predominantly 
converted to heat and partially used for non-mechanical activity of basal metabolism 
and for excitation-contraction coupling[31, 32]. To generate the same external power, 205 
myocardial oxygen consumption is lower when the myocardium oxidizes glucose and 
lactate than when the myocardium is fuelled by fatty acid β-oxidation. When glucose 
and palmitate oxidation are compared, the complete oxidation of 1 palmitate molecule 
generates 105 molecules of ATP and consumes 46 atoms of oxygen, whereas the 
complete oxidation of 1 molecule of glucose generates 31 molecules of ATP and 210 
consumes 12 atoms of oxygen[15, 33]. Therefore, the phosphate/oxygen ratio of 
oxidative phosphorylation (the ratio of the number of molecules of ATP produced per 
atom of oxygen reduced by the mitochondrial electron transport chain) is higher for 
glucose than for palmitate. However, increasing the rate of fatty acid uptake of the 
heart by elevating plasma free fatty acid concentrations with an infusion of heparin 215 
and triglyceride emulsion increases myocardial oxygen consumption by 
approximately 25% without changing the mechanical power of the left ventricle[34, 
35]. This difference is larger than the difference of the phosphate/oxygen ratio, which 
may be explained by increased uncoupling of mitochondrial oxidative 
phosphorylation and greater futile cycling during fatty acid oxidation[15]. 220 
 
4. Cardiac lipotoxicity 
Mismatch between the uptake and oxidation of long-chain fatty acids in the 
myocardium induces lipotoxicity characterized by the accumulation of triglycerides, 
diacylglycerols, ceramides, and other lipids. Myocardial lipotoxicity may result in 225 
cardiomyocyte apoptosis, interstitial fibrosis, and cardiac dysfunction, and may 
promote insulin resistance[36]. Heart failure is frequently accompanied by 
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cardiomyocyte lipid accumulation and a clear correlation between increased 
myocardial triglyceride content and decreased cardiac function has been established in 
rodents and humans. The accumulation of intramyocardial lipids in dysfunctional and 230 
failing hearts led to the hypothesis that toxic lipids are mediators of cardiac 
dysfunction. The turnover of triglycerides in the heart is very rapid (approximately 5 
hours) compared to adipose tissue (200-270 days)[37, 38]. Consequently, cardiac 
triglyceride accumulation is not inert but reflects a metabolic perpetuation of an 
imbalance between fatty acid uptake and oxidation. Triglycerides are unlikely the 235 
cause of the deterioration of cardiac function. Mice transgenic for diacylglycerol 
acyltransferase1 in the heart display normal cardiac function despite increased 
accumulation of triglycerides in the myocardium[39]. In contrast, accumulation of 
ceramides and diacylglycerols alter intracellular signaling pathways and promote 
apoptotic cell death. Ceramides can trigger apoptosis by inducing the release of 240 
cytochrome c from the mitochondria[40]. Diacylglycerols may interfere with the 
cardiac insulin-signaling cascade by activating protein kinase C, leading to decreased 
glucose uptake[41]. 
Cardiac dysfunction in obese and diabetic animals and in humans is unambiguously 
associated with prominent lipotoxicity[42]. The metabolic alterations associated with 245 
diabetic cardiomyopathy include excessive rates of myocardial fatty acid uptake and 
fatty acid oxidation coupled with reduced glucose utilization. In patients with 
insufficiently controlled type 1 diabetes mellitus, the heart is glucose-starved due a 
lack of insulin action and is forced to oxidize fatty acids as an alternative substrate to 
maintain cellular ATP levels. On the other hand, the type 2 diabetic heart is flooded 250 
with fatty acids, leading to inhibition of glucose oxidation in the mitochondria[42]. In 
both types of diabetes, metabolic flexibility is lost. Increased free fatty acids in 
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cardiomyocytes may activate the peroxisome proliferator‐activated receptor α 
(PPARα) pathway. Ligand activation of the transcription factor PPARα increases 
cellular utilization of fatty acids by up-regulating a subset of genes that promote fatty 255 
acid uptake and genes that increase fatty acid ß-oxidation[43]. PPARα increases 
pyruvate dehydrogenase kinase 4 expression, which together with negative feedback 
of fatty acid oxidation reaction products decreases glucose oxidation[44]. 
Cardiac steatosis and reduced myocardial function are observed in mouse models of 
increased fatty acid utilization induced by cardiac‐restricted transgenic expression of 260 
long‐chain acyl CoA synthetase 1[45], fatty acid transport protein 1[46], or 
PPARα[47]. In clear opposition, myocardial overexpression of adipose triglyceride 
lipase leads to reduced fatty acid oxidation, is accompanied by reduced triglycerides 
stores and increased insulin sensitivity and glucose oxidation, and protects against 
pressure overload-induced cardiomyopathy[48]. In a murine model of streptozotocin-265 
induced diabetes, cardiomyocyte-specific adipose triglyceride lipase expression 
protected against the development of diabetic cardiomyopathy[49].  Diabetes-induced 
increases in myocardial triglycerides, lipotoxic intermediate accumulation (ceramides, 
diacylglycerols, palmitoyl coenzyme A), and cardiac dysfunction were inhibited in 
mice with adipose triglyceride lipase expression under control of the myosin heavy 270 
chain promoter. Furthermore, these mice exhibited decreased reliance on palmitate 
oxidation and blunted PPARα activation[49]. 
The importance of fine-tuning of lipid homeostasis in the myocardium is underscored 
by the capacity of cardiomyocytes to export triglycerides via secretion of spherical 
lipoproteins[50]. In agreement, the heart expresses the two lipoprotein-assembly 275 
proteins that are mandatory for bulk secretion of triglycerides i.e. microsomal 
triglyceride transfer protein and apolipoprotein (apo) B. Transgenic mice 
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overexpressing a full length human apo B transgene are protected against obesity-
induced cardiac steatosis and lipotoxic heart disease[51], which clearly supports a 
protective role of lipoprotein secretion in the myocardium. Apo B expression in the 280 
myocardium also prevents cardiac dysfunction in diabetic mice[52]. Similarly, apo B 
production in the myocardium attenuates lipotoxic heart disease induced by free fatty 
acid oversupply secondary to lipoprotein lipase overexpression in the heart[53]. 
 
5. Impact of fatty acids on heart failure: experimental animal studies and clinical 285 
data 
The data presented in this section reflect a reductionist approach and should be 
interpreted cautiously. As already stated, a healthy diet should be thought of as a 
whole and interactions between various nutrients is very often the real biological 
source of protection rather than any small change in specific nutrients[13]. 290 
 
5.1. Saturated fatty acids 
Higher plasma saturated fatty acids, especially palmitic acid (C16:0) and myristic acid 
(C14:0), were independently associated with incident heart failure in both men and 
women in the Atherosclerosis Risk in Communities Study[54]. Saturated fatty acids 295 
may directly promote the development of heart failure by inducing lipotoxicity[55]. 
However, most experimental animal studies on the role of saturated fatty acids in 
cardiac dysfunction have been based on obesogenic high-fat diets. Obesity-associated 
inflammation and systemic insulin resistance confound experimental investigations 
designed to study the causal role of saturated fatty acids in cardiac dysfunction and 300 
heart failure. The myristate-containing ceramide species C14-ceramide has been 
implicated in the pathogenesis of lipotoxic cardiomyopathy in a milk-fat based diet 
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model that was associated with an approximately 20% increase of body weight[55]. A 
cocoa butter derived high-fat diet (containing mainly palmitate (C16:0) and stearate 
(C18:0)) did not have major effects on cardiac structure and function compared to a 305 
low fat diet in sham-operated mice and in mice with pressure overload induced by 
transverse aortic constriction[56, 57]. This cocoa butter derived high-fat diet resulted 
in minor effects[56] or no effects[57] on body weight. Taken together, many 
experimental studies on the effect of dietary saturated fatty acids are confounded by 
changes in body weight. A direct causal role of saturated fatty acids in cardiac 310 
dysfunction and heart failure is essentially unproven.  
 
5.2. Monounsaturated fatty acids 
Feeding experiments in rodents, pigs, and non-human primates published between 
1960 and 1986 suggested that consumption of erucic acid (C22:1, n−9) and cetoleic 315 
acid (C22:1, n−11) resulted in cardiac steatosis and fibrosis[58-61]. Long-chain 
monounsaturated fatty acids (C20:1, C22:1, C24:1) are predominantly oxidized in 
peroxisomes rather than in mitochondria, which lack membrane-transporting enzymes 
for long-chain fatty acids[62, 63]. Fatty acid oxidation in peroxisomes produces 
reactive oxygen species and various cytosolic lipid metabolites that can cause 320 
cardiotoxicity and impaired myocardial function[15, 25, 62]. 
Erucic acid comprises 30-60% of fatty acids in unmodified rapeseed oil. The evidence 
from animal feeding studies on the potential cardiotoxicity of long-chain 
monounsaturated fatty acids[58-61] led Canadian farmers to develop Canola[63]. 
Canola is a modified rapeseed oil and is the acronym of CANadian Oil Low in erucic 325 
Acid. However, the potential toxicity of long-chain monounsaturated fatty acids was 
largely forgotten in recent decades till Imamura et al.[63] investigated the association 
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between long-chain monounsaturated fatty acids and the incidence of congestive heart 
failure in two prospective cohorts. After multivariable adjustment, higher plasma 
phospholipid levels of C22:1 and C24:1  but not C20:1 were associated with greater 330 
congestive heart failure incidence in both the Cardiovascular Health Study and in the 
Atherosclerosis Risk in Communities Study Minnesota subcohort[63]. These 
associations existed for ischemic congestive heart failure, valvular congestive heart 
failure, and non-ischemic non-valvular ischemic heart failure. 
Sources of long-chain monounsaturated fatty acids include generally more healthy 335 
foods (fish, mustard seeds and oil, salad oils, and poultry) and less healthy foods 
(processed meats and mixed meals e.g. pizza and meat sandwiches). Since fish intake 
has been inversely associated with the incidence of congestive heart failure[64], the 
potential benefits of long-chain omega-3 polyunsaturated fatty acids likely outweigh 
any potential harmful effects of long-chain monounsaturated fatty acids. 340 
 
5.3. Omega-3 polyunsaturated fatty acids 
A meta-analysis of 7 prospective studies with a total of 176 441 subjects and 5 480 
incident cases of heart failure concluded that fish intake and intake of marine omega-3 
fatty acids (eicosapentaenoic acid (EPA) (C20:5, n−3) and docosahexaenoic acid 345 
(DHA) (C22:6, n−3)), lowered the risk of heart failure[65]. Plasma phospholipid 
levels of α-linolenic acid (C18:3, n−3) and dietary intake of α-linolenic acid were not 
associated with incident congestive heart failure in the Cardiovascular Health Study, a 
prospective cohort study of adults aged 65 years or older in the USA[66]. 
 350 
5.4. Omega-6 polyunsaturated fatty acids 
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After adjustment for age and other confounders, an inverse relationship was observed 
between plasma phospholipid arachidonic acid (C20:4, n−6) levels and congestive 
heart failure incidence in women but not in men in the Atherosclerosis Risk in 
Communities Study Minnesota subcohort[54]. An inverse relationship between 355 
plasma phospholipid linoleic acid (C18:2, n−6) levels and congestive heart failure 
incidence was observed in a model adjusted for age and sex[54]. In contrast, 
phospholipid dihomo γ-linolenic acid (C20:3, n−6) levels were positively associated 
with incident heart failure in a model adjusted for age and sex[54]. However, after 
adjustment for other confounders, the associations of linoleic acid levels and dihomo 360 
γ-linolenic acid levels with incident heart failure were attenuated. In a nested case-
control analysis of the Physicians’ Health Study, no association between total plasma 
omega-6 polyunsaturated fatty acids and risk of developing heart failure was observed 
in male US physicians[67]. 
 365 
6. Impact of lipoprotein levels on heart failure: experimental animal studies and 
clinical data 
Epidemiological studies support a strong association between metabolic 
cardiovascular risk factors and heart failure incidence. The risk for incident heart 
failure in the Framingham Heart Study was 2.4-fold higher in diabetic men and 5.0-370 
fold higher in diabetic women independent of age, coronary disease, hypertension, 
and body mass index[68]. In Framingham Heart Study participants free of coronary 
heart disease at baseline, low high-density lipoprotein (HDL) cholesterol and high 
non-HDL cholesterol were independently associated with heart failure incidence after 
adjustment for interim myocardial infarction and clinical covariates[69]. However, 375 
plasma non-HDL cholesterol levels strongly correlate with the intake of saturated 
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fat[70], which may confound the association between non-HDL and heart failure 
incidence. As stated in section 5.1, higher plasma saturated fatty acids, especially 
palmitic acid (C16:0) and myristic acid (C14:0), were independently associated with 
incident heart failure in both men and women in the Atherosclerosis Risk in 380 
Communities Study[54]. 
 
6.1. Non-HDL lipoproteins 
Based on echocardiographic data, an early cardiomyopathy characterized by systolic 
and diastolic dysfunction has been described in patients with primary 385 
hypercholesterolemia without evidence of coronary heart disease[71]. Experimental 
rabbit data are in agreement with the hypothesis that hypercholesterolemia has direct 
effects on the myocardium. Hypercholesterolemia in rabbits induces electrical 
remodelling of the heart, characterized by prolongation of the action potential and of 
the heart rate corrected QT interval, increased repolarization dispersion, and 390 
vulnerability to ventricular fibrillation[72]. Using tissue Doppler imaging, systolic 
and diastolic dysfunction has been demonstrated in hypercholesterolemic rabbits[73]. 
Data on the effect of cholesterol on in vivo systolic and diastolic function are 
paralleled by observations in isolated cardiomyocytes showing a decrease in the 
maximum rate of cardiomyocyte shortening and the maximum rate of cardiomyocyte 395 
relaxation[74, 75]. Based on these observations, the term ‘cholesterol 
cardiomyopathy’ has been introduced[74]. However, these rabbit studies should be 
interpreted with caution. Indeed, plasma cholesterol levels in these studies were 
approximately 500 mg/dl[73] and 800 mg/dl[74], which is rarely observed in humans. 
Taken together, none of these experimental animal intervention studies have 400 
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investigated the impact of a pathophysiologically relevant degree of 
hypercholesterolemia on the development of heart failure.  
Van Craeyveld et al.[76] have demonstrated that lipid lowering gene transfer in 
hypercholesterolemic mice results in reduced infarct expansion, decreased ventricular 
remodelling, and improved left ventricular contractility and relaxation post-405 
myocardial infarction. This study was performed in a model of permanent ligation of 
the left anterior descending coronary artery. The interpretation of the experimental 
results in this model should take into account the effect of lipid lowering on infarct 
healing. Since lipid lowering improved infarct healing and attenuated infarct 
expansion[76], direct effects of lipid lowering on the myocardium cannot be 410 
unambiguously proven in this model. 
As stated supra, high non-HDL cholesterol levels were independently associated with 
heart failure incidence after adjustment for interim myocardial infarction and clinical 
covariates in Framingham Heart Study participants free of coronary heart disease at 
baseline[69]. These prospective data are in agreement with earlier cross-sectional 415 
studies showing that post-infarct ejection fraction is lower in patients with elevated 
non-HDL cholesterol levels[77, 78]. Furthermore, mortality rates in patients 
developing congestive heart failure were 20% lower with simvastatin treatment 
compared with placebo in the Scandinavian Simvastatin Survival Study (4S)[79] but 
these data are observational. In contrast, data from randomized clinical trials 420 
evaluating the effects of statins in heart failure patients seem to contradict a role of 
non-HDL lipoproteins. In the CORONA randomized clinical trial[80], a total of 5011 
patients at least 60 years of age with New York Heart Association class II, III, or IV 
ischemic, systolic heart failure were randomly assigned to receive 10 mg of 
rosuvastatin or placebo per day. The primary outcome (death from cardiovascular 425 
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causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 692 patients in 
the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% 
confidence interval, 0.83 to 1.02; P=0.12) during a median follow-up of 32.8 months. 
In a pre-specified secondary analysis, there were fewer hospitalizations for 
cardiovascular causes in the rosuvastatin group (2193) than in the placebo group 430 
(2564) (P<0.001)[80]. In the GISSI-HF trial, rosuvastatin 10 mg daily did not affect 
clinical outcomes in patients with chronic heart failure of any cause[81]. At least two 
factors may explain the apparent discrepancy between the results of these critically 
important trials on the one hand and the epidemiological observations and 
experimental animal studies on the other hand. Firstly, lipid lowering before the onset 435 
of overt heart failure may be critical to observe beneficial effects. Secondly, the 
precise biochemical effects of statins should be considered.  Statins inhibit 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA) reductase, which converts 3-hydroxy-3-
methylglutaryl-CoA to mevalonate. However, cholesterol biosynthesis is only one of 
the functions of the mevalonate pathway. Blocking the mevalonate pathway by statins 440 
also inhibits the synthesis of isopentenyl pyrophosphate. Isopentenyl pyrophosphate is 
a unique intermediate of the mevalonate pathway. This molecule is not only a 
building block for cholesterol synthesis but is also is required for the post-
transcriptional enzymatic isopentenylation of selenocysteine tRNA and its maturation 
to a functional tRNA molecule.  Inhibition of isopentenyl pyrophosphate synthesis by 445 
statins results in a decrease in available selenoproteins[82]. Among the 25 
selenoproteins in mammals, the family of glutathione peroxidases is a major group. 
Each of these enzymes reduces lipid and hydrogen peroxides to lipid alcohols and 
water, respectively, and does so while oxidizing glutathione to glutathione 
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disulfide[83]. A reduction of myocardial glutathione peroxidases may impair cardiac 450 
function via increased oxidative stress[83].  
Farnesyl pyrophosphate is a further downstream intermediate of the mevalonate 
pathway and is a precursor for cholesterol. The farnesyl moiety from farnesyl 
pyrophosphate is utilized for post-translational modification of proteins including 
small GTPases. Farnesyl pyrophosphate is also a precursor for geranylgeranyl 455 
pyrophosphate, which is similarly involved in post-translational modification of 
proteins. Furthermore, farnesyl pyrophosphate is a precursor of dolichol, heme-A, and 
ubiquinone (coenzyme Q10). Thus, endogenous coenzyme Q10 synthesis is blocked 
by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)[84]. 
Coenzyme Q10 is a component of the electron transport chain in the mitochondria and 460 
participates in aerobic cellular respiration leading to the production of ATP. Low 
plasma coenzyme Q10 levels are an independent risk factor for worsened outcomes in 
heart failure[85]. In a small recent randomised trial enrolling 420 patients, treatment 
with coenzyme Q10 in chronic heart failure patients reduced major adverse 
cardiovascular events[86]. Taken together, beneficial effects of cholesterol lowering 465 
on cardiac function induced by statins may be partially offset by the statin-induced 
reduction of coenzyme Q10 and by decreased myocardial glutathione peroxidase 
activity secondary to the statin-induced decline of isopentenylation of selenocysteine 
tRNA. 
The topic of the side effects of statins is important and a source of significant 470 
controversies. One area of particular interest concerning the relation between serum 
cholesterol, statin use, and heart failure is the effect of statins on diabetes incidence. 
Using data from 20 randomised controlled trials, Swerdlow et al.[87] recently showed 
that statin treatment increased the risk of incident type 2 diabetes, with an odds ratio 
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(OR) of 1.12 (95% CI 1.06–1.18) versus controls, which confirms previous reports. 475 
Since the risk for incident heart failure in the Framingham Heart Study was 2.4-fold 
higher in diabetic men and 5.0-fold higher in diabetic women independent of age, 
coronary disease, hypertension, and body mass index[68], increased incidence of 
diabetes on statins may counteract potential beneficial effects of cholesterol lowering 
on cardiac function. Using a mendelian randomization approach based on single 480 
nucleotide polymorphisms in the HMG-CoA reductase gene, Swerdlow et al.[87] 
demonstrated that reduced HMG-CoA reductase activity results in a slightly increased 
risk of type 2 diabetes (rs17238484-G allele odds ratio per allele 1.02, 95% 
confidence interval 1.00–1.05; rs12916 allele 1.06, 1.03–1.09). Therefore, it appears 
that an increased risk of type 2 diabetes is at least partially conferred by HMG-CoA 485 
reductase activity itself and is thus an on-target effect of statins. More recently, an 
observational study has suggested that transmembrane cholesterol transport is linked 
to the development of type 2 diabetes mellitus[88]. In a cross-sectional analysis in the 
Netherlands, the prevalence of type 2 diabetes in patients with familial 
hypercholesterolemia was significantly lower than among unaffected relatives[88]. 490 
LDL receptor-negative mutation carriers had the lowest prevalence followed by LDL-
receptor deficient mutation carriers, apolipoprotein B mutation carriers, and 
unaffected relatives. Although these cross-sectional data are susceptible to survival 
bias, they suggest that higher LDL receptor activity may promote the development of 
type 2 diabetes mellitus. 495 
 
6.2. HDL lipoproteins 
Low HDL cholesterol levels were independently associated with heart failure 
incidence after adjustment for interim myocardial infarction and clinical covariates in 
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Framingham Heart Study participants free of coronary heart disease at baseline[69]. 500 
Earlier cross-sectional studies had demonstrated that post-infarct ejection fraction is 
lower in patients with low HDL cholesterol levels[77, 78]. Low HDL cholesterol 
levels and low levels of apolipoprotein (apo) A-I, the main apo of HDL,  indicate an 
unfavorable prognosis in patients with heart failure independent of the aetiology[89, 
90].  505 
The observed relationship between HDL and heart failure in epidemiological studies 
might reflect residual confounding. Low HDL may be an integrated biomarker of 
adverse metabolic processes such as abnormal metabolism of triglyceride rich 
lipoproteins, insulin resistance, and ongoing tissue inflammation[91]. Crosstalk 
between inflammatory processes and metabolic dysregulation may accelerate the 510 
development of heart failure[92].  
Human apo A-I gene transfer inhibits the development of diabetic cardiomyopathy in 
rats[93]. We have shown that HDL raising gene transfer raises both capillary density 
and relative vascularity in the myocardium of hypercholesterolemic mice and 
improves diastolic function in these mice as indicated by an increased peak rate of 515 
isovolumetric relaxation[94]. Furthermore, we have recently demonstrated that 
selective HDL raising human apo A-I gene transfer increases survival, reduces infarct 
expansion, attenuates left ventricular dilatation, and enhances systolic and diastolic 
cardiac function post-myocardial infarction in mice[95]. Molecular effects of HDL on 
the myocardium have been recently reviewed in detail[96]. Taken together, these 520 
experimental intervention studies corroborate the view that HDL-targeted therapies 
might be beneficial in prevention and/or treatment of heart failure. 
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CONCLUSION 525 
The daily turnover of ATP in the human heart (13 mol or more than 6 kg) is many 
times higher than the weight of the heart[18]. Metabolic homeostasis requires a fine-
tuning of cardiac metabolism of different substrates. Notwithstanding a retro control 
of fatty acid and glucose utilization, the heart functions best when it oxidizes both 
substrates simultaneously[19]. Mismatch between the uptake and oxidation of long-530 
chain fatty acids in the myocardium induces lipotoxicity characterized by the 
accumulation of triglycerides, diacylglycerols, ceramides, and other lipids. 
Myocardial lipotoxicity may result in cardiomyocyte apoptosis, interstitial fibrosis, 
and cardiac dysfunction, and may promote insulin resistance[36]. Although lipotoxic 
heart disease is most evident in subjects with obesity and in patients with diabetes, 535 
epidemiological studies support a potential direct impact of fatty acids on the 
development of heart failure independent on any effect on coronary heart disease. 
Specifically, plasma levels of specific saturated fatty acids (C14:0 and C16:0) and of 
long-chain monounsaturated fatty acids (C22:1, C24:1) are positively associated with 
incidence of congestive heart failure[54, 63]. In contrast, intake of marine omega-3 540 
polyunsaturated fatty acids (C20:5, n−3 and C22:6, n−3) lowered the risk of heart 
failure[65]. The relation between the intake of omega-6 polyunsaturated fatty acids 
and heart failure is unclear. 
High non-HDL cholesterol levels are independently associated with heart failure 
incidence after adjustment for interim myocardial infarction and clinical covariates in 545 
Framingham Heart Study participants free of coronary heart disease at baseline[69]. 
Statins may be beneficial when started before the development of heart failure[79] but 
a clinically significant effect of initiating statin therapy in patients with established 
heart failure is insufficiently or not corroborated by randomized trials[80, 81]. A role 
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of HDL in myocardial biology and heart failure is supported by observational 550 
studies[69] and experimental human apo A-I gene transfer studies[93-95]. 
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FUTURE PERSPECTIVE 
The incidence and prevalence of heart failure are increasing[3]. Heart failure is the 
cardiovascular disease of this century in Europe and in the United States. As the 555 
population ages, heart failure will continue to be a growing public health problem. 
Future directions are summarized in Table 1.  
The molecular basis of lipotoxic heart disease, specifically which lipid species are 
causing cardiac dysfunction, is insufficiently known. Lipotoxic heart disease and its 
relationship with cardiac cellular metabolism will remain an area of very intensive 560 
investigation. Lipidomics studies are required for quantification of individual 
ceramide species, diacylglycerol species, and species of other lipid classes to increase 
our insights into myocardial lipotoxicity. 
Approximately 50% of patients with clinical features of chronic heart failure have 
heart failure with reduced ejection fraction (HFrEF) and 50% suffer from heart failure 565 
with preserved ejection fraction (HFpEF)[97]. HFpEF is a complex clinical syndrome 
that is characterized by classical heart failure symptoms with increased left ventricular 
filling pressure and preserved left ventricular ejection fraction. It is usually defined as 
heart failure with an ejection fraction equal to or greater than 50%. This heart failure 
subtype disproportionately affects women and the elderly and is commonly associated 570 
with other cardiovascular comorbidities, such as hypertension, obesity, and diabetes. 
Most clinical heart failure trials have been focused on patients with HFrEF. Inhibition 
of the renin-angiotensin-aldosterone and sympathetic nervous systems improves 
survival and decreases hospitalizations in patients with HFrEF. In contrast to these 
advances in treatment of patients with HFrEF, drug strategies with strong evidence in 575 
HFrEF have proved unsuccessful in HFpEF and the mortality in patients with HFpEF 
has remained unchanged. Since diastolic abnormalities constitute part of the 
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pathophysiology of HFpEF, HDL-targeted therapies might be beneficial in prevention 
and/or treatment of this particular type of heart failure. 
The effectiveness of statins in patients with heart failure will remain an area of 580 
investigation. In the Swedish Heart Failure Registry, statins were associated with 
improved outcomes in patients with HFrEF, specifically in the presence of ischemic 
heart disease[98]. These real world data contrast with previous randomized controlled 
trials[80, 81]. Additional randomized controlled trials with more generalized inclusion 
or focused on ischemic heart disease may be warranted. Based on the analysis of a 585 
Japanese chronic heart failure registry, statin use was associated with improved 
mortality rates in HFpEF patients, mainly attributable to reductions in sudden death 
and noncardiovascular death[99]. Therefore, randomized controlled trials evaluating 
statins in patients with HFpEF are certainly warranted. 
Consumption of flaxseed is a potential dietary intervention that might reduce heart 590 
failure incidence. Flaxseed contains α-linolenic acid (C18:3, n−3), lignans, and fiber. 
The Flaxseed for Peripheral Arterial Disease (FlaxPAD) Trial was a double-blinded 
randomized trial, in which patients with peripheral arterial disease, of whom 75% had 
hypertension, were randomized to 30 g of milled flaxseed or placebo daily for 6 
months[100]. In the active treatment group, significant reductions of systolic (- 10 595 
mm Hg) and diastolic blood pressure (-7 mm Hg) were observed. The 
antihypertensive effect was achieved selectively in hypertensive patients. Plasma α-
linolenic acid (C18:3, n−3) increased with ingestion of flaxseed and was inversely 
associated with blood pressure. This effect may have been mediated via an inhibition 
of soluble epoxide hydrolase, which altered oxylipin concentrations[101]. 600 
In a randomized sample from the PREDIMED trial, a reduction of N-terminal pro-
brain natriuretic peptide, a biomarker for heart failure, was observed in individuals at 
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high risk of cardiovascular disease who improved their diet toward a traditional 
Mediterranean diet compared with those assigned to a low-fat diet[102]. The critical 
question whether the effect of a traditional Mediterranean diet supplemented with 605 
extra-virgin olive oil or with mixed nuts reduces the incidence of heart failure should 
be addressed in a statistically sufficiently powered clinical trial in an elderly 
population at high risk for heart failure. 
 
EXECUTIVE SUMMARY 610 
• Epidemiological perspective on heart failure 
*As the population ages, heart failure will continue to be a growing public 
health problem. 
• Diet and prevention of coronary heart disease  
* The PREDIMED study is a landmark trial in primary prevention. 615 
* The interactions between various nutrients is the real biological source of 
protection rather than any small change in specific nutrients. 
• Lipids as fuel for the heart 
* The Randle cycle, also known as the glucose fatty-acid cycle, describes the 
reciprocal relationship between fatty acid and glucose metabolism. The 620 
mechanical efficiency of the heart is lower when fatty acids are oxidized. 
• Cardiac lipotoxicity 
* Mismatch between the uptake and oxidation of long-chain fatty acids in the 
myocardium induces lipotoxicity characterized by the accumulation of 
triglycerides, diacylglycerols, ceramides, and other lipids.  625 
* Lipotoxicity may result in cardiomyocyte apoptosis, interstitial fibrosis, and 
cardiac dysfunction, and may promote insulin resistance. 
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• Impact of fatty acids on heart failure 
* Plasma levels of specific saturated fatty acids (C14:0 and C16:0) and of 
long-chain monounsaturated fatty acids (C22:1, C24:1) are positively 630 
associated with incidence of congestive heart failure.  
* In contrast, intake of marine omega-3 polyunsaturated fatty acids (C20:5, 
n−3 and C22:6, n−3) lowered the risk of heart failure.  
* The relation between the intake of omega-6 polyunsaturated fatty acids and 
heart failure is unclear. 635 
• Impact of lipoprotein levels on heart failure 
* High non-HDL cholesterol levels and low HDL cholesterol levels are 
independently associated with heart failure incidence after adjustment for 
interim myocardial infarction and clinical covariates.  
* The effect of statins in patients with established heart failure (HFrEF and 640 
HFpEF) remains controversial and is an area of active investigation. 
* HDL-targeted therapies might be beneficial for prevention and/or treatment 
of heart failure. 
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REFERENCE ANNOTATIONS 
Reference 3 
* This paper represents an authoritative and recent overview of cardiovascular 
epidemiology in Europe. 940 
Reference 11 
** This paper presents the results of the landmark primary prevention PREDIMED 
trial. 
Reference 42 
** This review is an excellent discussion of fatty acid metabolism and alterations of 945 
lipid homeostasis in the diabetic heart. 
Reference 63 
** This prospective epidemiological study represents the rediscovery of the 
importance of long-chain monounsaturated fatty acids in cardiac metabolism and 
development of heart failure. 950 
Reference 65 
* This paper is an authoritative meta-analysis demonstrating the effect of dietary 
intake of C20:5, n−3 and C22:6, n−3 on the incidence of congestive heart failure. 
Reference 76 
** This experimental murine intervention study unequivocally demonstrates the 955 
impact of plasma cholesterol on the development of ischemic heart failure 
independent of any effects on the coronary circulation. 
Reference 96 
** This review contains a detailed description of molecular effects of HDL on the 
myocardium. 960 
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LEGEND TO THE FIGURE 
Figure 1. Schematic overview of fatty acid ß-oxidation in cardiomyocytes and its 
reciprocal relationship with glucose metabolism. Fatty acids enter the 
cardiomyocyte either by passive diffusion or via protein carrier-mediated pathways 965 
including CD36 (fatty acid translocase) and fatty acid transport protein (FATP) 1. In 
the cytosol, fatty acids are esterified to fatty-acyl-CoA by fatty-acyl-CoA synthase. 
Fatty-acyl-CoA is then esterified to triglycerides (TG) or converted to fatty-acyl-
carnitine via carnitine palmitoyltransferase I (CPT1), which is an integral membrane 
protein that associates with the outer mitochondrial membrane. Carnitine-970 
acylcarnitine translocase (CACT) is responsible for transporting fatty-acyl-carnitine 
across the inner mitochondrial membrane. In the mitochondrial matrix, fatty-acyl-
carnitine is converted to fatty-acyl-CoA by carnitine palmitoyltransferase II (CPT2). 
The fatty-acyl-CoA enters the cycle of ß-oxidation pathway involving formation of 
trans-2-enoyl-CoA, 3-hydroxyacyl-CoA, beta-ketoacyl-CoA, and back to fatty-acyl-975 
CoA via the enzymes acyl-CoA dehydrogenase, enoyl-CoA hydratase 1, 3-
hydroxyacyl-CoA dehydrogenase and beta-ketoacyl-CoA thiolase, respectively. 
Acetyl-CoA produced in the ß-oxidation pathway enters the tricarboxylic acid cycle 
(TCA cycle) (Krebs cycle, citric acid cycle), which results in the production of 
FADH2 and NADH. In certain conditions, fatty-acyl-CoA can be cleaved into fatty 980 
acid anions (FA-) and CoA via the enzyme mitochondrial thioesterase (MTE). The 
FA- can then exit the mitochondrial matrix via an uncoupling protein (UCP). The 
electrons from cellular dehydrogenases in the ß-oxidation pathway and TCA cycle are 
transferred horizontally in the electron transport chain in the inner mitochondrial 
membrane accompanied by a vertical transfer of dehydrogenase derived protons from 985 
the mitochondrial matrix into the intermembrane space creating an electrochemical 
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proton gradient across the inner mitochondrial membrane. This gradient is the driving 
force in formation of ATP from ADP through the FO/F1-ATP synthase complex. 
UCPs in the inner mitochondrial membrane can dissipate the proton gradient so that 
free energy to drive ATP synthesis is lost. 990 
Glucose can enter the cardiomyocyte via GLUT4 or GLUT1 transporters. Pyruvate 
decarboxylation is the key irreversible step in carbohydrate oxidation and is catalyzed 
by pyruvate dehydrogenase, which is located in the mitochondrial matrix. Increased 
generation of acetyl-CoA derived from fatty acid β-oxidation decreases pyruvate 
dehydrogenase activity via the activation of pyruvate dehydrogenase kinase and the 995 
subsequent phosphorylation and inhibition of pyruvate dehydrogenase. Both an 
increased acetyl CoA/CoA ratio and an increased NADH/NAD+ ratio result in 
activation of pyruvate dehydrogenase kinase.  
